RAYONT, INC. Inactive Instrument
Rayont, Inc. Stock Other OTC
Equities
RAYT
US75508M1009
Biotechnology & Medical Research
Financials (USD)
| Sales 2021 | 2.97M | Sales 2022 | 2.84M | Capitalization | 45.69M |
|---|---|---|---|---|---|
| Net income 2021 | - | Net income 2022 | - | EV / Sales 2021 | 47.8 x |
| Net Debt 2021 | 2.4M | Net Debt 2022 | 7.78M | EV / Sales 2022 | 18.8 x |
| P/E ratio 2021 |
293
x | P/E ratio 2022 |
186
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 48.18% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 20-03-30 | |
Ilenna Copley
COO | Chief Operating Officer | - | 22-05-15 |
Dhurata Toli
BRD | Director/Board Member | 48 | 21-03-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jason Sunstein
BRD | Director/Board Member | 52 | 22-04-20 |
Dhurata Toli
BRD | Director/Board Member | 48 | 21-03-24 |
| Chief Executive Officer | 48 | 20-03-30 |
Rayont Inc. operates in the personalized natural healthcare sector in United States and Australia. The Company uses scientific tools, such as deoxyribonucleic acid (DNA), microbiome, iridology and other tests to diagnose and personalize the prescription of natural complementary medicine products, services and treatments to its patients in the markets the Company operate. The Company produces a range of products, including proteins, green blends, sports nutrition, weight management and maintenance, and health and wellness products. The Company's subsidiaries include Rayont (Malaysia) Sdn Bhd, Rayont International (L) Limited, Rayont (Australia) Pty Ltd and Prema Life (USA) Inc.
Calendar
2024-05-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
